Patents by Inventor James I. Andorko

James I. Andorko has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250236647
    Abstract: Provided for herein are viral particles comprising a heterologous viral glycoprotein and a targeting moiety, wherein the targeting moiety comprises a polypeptide comprising a formula of T-S1, wherein T is a target binding domain and S1 is a stalk portion. The stalk portion may comprise a variant Fc domain. The stalk portion may comprise a flexible polypeptide domain. The targeting moiety comprising the formula T-S1 may be incorporated into a viral particle to assist with targeting such particles to a specific cell type. Also provided for herein are compositions comprising the same, and methods of using the same.
    Type: Application
    Filed: February 11, 2025
    Publication date: July 24, 2025
    Inventors: Bruce C. Schnepp, Philip R. Johnson, James I. Andorko
  • Publication number: 20250171746
    Abstract: Provided for herein are mutant VSV-G polypeptides, compositions comprising the same, and methods of using the same. Also provided for herein are polypeptides and compositions that bind to CD7 and uses thereof. Also provided for herein are polypeptides and compositions that bind to CD8 and uses thereof.
    Type: Application
    Filed: January 31, 2025
    Publication date: May 29, 2025
    Inventors: Ronnie M. Russell, Philip R. Johnson, James I. Andorko, Mohit Sachdeva, Bruce Schnepp, Michael Marinelli, Jeffrey Foss, Debasish Boral
  • Publication number: 20250051797
    Abstract: Provided for herein are compositions and methods that can be used to transduce cells and deliver genetic information that can then be expressed in the transduced cell. Also provided herein are methods of treating a disease in a subject using the compositions and methods provided.
    Type: Application
    Filed: December 12, 2022
    Publication date: February 13, 2025
    Inventors: James I. Andorko, Mohit Sachdeva
  • Publication number: 20240287472
    Abstract: Provided for herein are mutant VSV-G polypeptides, compositions comprising the same, and methods of using the same. Also provided for herein are polypeptides and compositions that bind to CD7 and uses thereof. Also provided for herein are polypeptides and compositions that bind to CD8 and uses thereof.
    Type: Application
    Filed: April 26, 2024
    Publication date: August 29, 2024
    Inventors: Ronnie M. Russell, Philip R. Johnson, James I. Andorko, Mohit Sachdeva, Bruce Schnepp, Michael Marinelli, Jeffrey Foss, Debasish Boral
  • Publication number: 20240066119
    Abstract: The present disclosure relates to methods for eliciting an immune response to a cancer antigen in a subject in need thereof by introducing directly into at least one lymph node of the subject, and preferably at least two lymph nodes, a therapeutically effective amount of a cancer antigen and/or an adjuvant such that an immune response to the cancer antigen is activated or enhanced in the subject. The present disclosure also concerns pharmaceutical compositions that comprise a therapeutically effective amount of a cancer antigen and/or an adjuvant capable of mediating, and more preferably enhancing, activation of the immune system of a subject against cancer cells that are associated with any of a variety of cancers. The disclosure also relates to the use of such pharmaceutical compositions in the treatment or prevention of a cancer in a recipient subject.
    Type: Application
    Filed: January 12, 2022
    Publication date: February 29, 2024
    Inventors: Christopher M. JEWELL, James I. ANDORKO
  • Publication number: 20240059744
    Abstract: Provided for herein are viral particles comprising a heterologous viral glycoprotein and a targeting moiety, wherein the targeting moiety comprises a polypeptide comprising a formula of T-S1, wherein T is a target binding domain and S1 is a stalk portion. The stalk portion may comprise a variant Fe domain. The stalk portion may comprise a flexible polypeptide domain. The targeting moiety comprising the formula T-S1 may be incorporated into a viral particle to assist with targeting such particles to a specific cell type. Also provided for herein are compositions comprising the same, and methods of using the same.
    Type: Application
    Filed: July 25, 2023
    Publication date: February 22, 2024
    Inventors: Bruce C. Schnepp, Philip R. Johnson, James I. Andorko
  • Publication number: 20230293688
    Abstract: Provided for herein are fusogenic rhabdovirus glycoproteins and uses thereof, compositions comprising the same, and methods of using the same. Also provided for herein are pseudotyped viral particles comprising rhabdovirus glycoproteins as provided for herein and targeting moieties as provided for herein. Also provided are methods of generating and using the pseudotyped viral particles as provided for herein.
    Type: Application
    Filed: February 10, 2023
    Publication date: September 21, 2023
    Inventors: Ronnie M. Russell, Bruce Schnepp, James I. Andorko, Michael Marinelli, Mohit Sachdeva, Debasish Boral, Jeffery Foss
  • Publication number: 20230295332
    Abstract: Provided for herein are mutant VSV-G polypeptides, compositions comprising the same, and methods of using the same. Also provided for herein are polypeptides and compositions that bind to CD7 and uses thereof. Also provided for herein are polypeptides and compositions that bind to CD8 and uses thereof.
    Type: Application
    Filed: December 15, 2022
    Publication date: September 21, 2023
    Inventors: Ronnie M. Russell, Philip R. Johnson, James I. Andorko, Mohit Sachdeva, Bruce Schnepp, Michael Marinelli, Jeffrey Foss, Debasish Boral
  • Publication number: 20230279363
    Abstract: Provided for herein are mutant VSV-G polypeptides, compositions comprising the same, and methods of using the same. Also provided for herein are polypeptides and compositions that bind to CD7 and uses thereof. Also provided for herein are polypeptides and compositions that bind to CD8 and uses thereof.
    Type: Application
    Filed: January 20, 2023
    Publication date: September 7, 2023
    Inventors: Ronnie M. Russell, Philip R. Johnson, James I. Andorko, Mohit Sachdeva, Bruce Schnepp, Michael Marinelli, Jeffrey Foss, Debasish Boral
  • Patent number: 11054413
    Abstract: The present invention provides a device for assaying living cells comprising a substrate, wherein the substrate comprises one or more tethering molecules which adhere to the substrate and are capable of interacting with cell membranes of the cells, wherein the cells maintain a free-floating, non-adherent character when bound to the one or more tethering molecules.
    Type: Grant
    Filed: October 7, 2015
    Date of Patent: July 6, 2021
    Assignees: UNIVERSITY OF MARYLAND, COLLEGE PARK, UNIVERSITY OF MARYLAND, BALTIMORE
    Inventors: Stuart Martin, Christopher M. Jewell, James I. Andorko, Elisabeth Lily Sooklal, Rebecca Whipple Bettes, Kristi Chakrabarti
  • Patent number: 10071145
    Abstract: A method of inducing specific immune tolerance to myelin in an individual is provided. The method includes introducing directly into a lymph node of the individual an effective amount of a composition that contains a myelin antigen, a biodegradable material and at least one tolerogenic agent. The method is suitable for reducing the severity of symptoms of multiple sclerosis in individuals who suffer from primary-progressive multiple sclerosis (PPMS), and can halt or even reverse PPMS progression.
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: September 11, 2018
    Assignee: UNIVERSITY OF MARYLAND, COLLEGE PARK
    Inventors: Christopher M. Jewell, James I. Andorko, Lisa H. Tostanoski
  • Publication number: 20170173129
    Abstract: A method of inducing specific immune tolerance to myelin in an individual is provided. The method includes introducing directly into a lymph node of the individual an effective amount of a composition that contains a myelin antigen, a biodegradable material and at least one tolerogenic agent. The method is suitable for reducing the severity of symptoms of multiple sclerosis in individuals who suffer from primary-progressive multiple sclerosis (PPMS), and can halt or even reverse PPMS progression.
    Type: Application
    Filed: March 3, 2017
    Publication date: June 22, 2017
    Inventors: Christopher M. Jewell, James I. Andorko, Lisa H. Tostanoski
  • Patent number: 9610349
    Abstract: A method of inducing specific immune tolerance to myelin in an individual is provided. The method includes introducing directly into a lymph node of the individual an effective amount of a composition that contains a myelin antigen, a biodegradable material and at least one tolerogenic agent. The method is suitable for reducing the severity of symptoms of multiple sclerosis in individuals who suffer from primary-progressive multiple sclerosis (PPMS), and can halt or even reverse PPMS progression.
    Type: Grant
    Filed: June 26, 2015
    Date of Patent: April 4, 2017
    Assignee: University of Maryland, College Park
    Inventors: Christopher M. Jewell, James I. Andorko, Lisa H. Tostanoski
  • Publication number: 20160097769
    Abstract: The present invention provides a device for assaying living cells comprising a substrate, wherein the substrate comprises one or more tethering molecules which adhere to the substrate and are capable of interacting with cell membranes of the cells, wherein the cells maintain a free-floating, non-adherent character when bound to the one or more tethering molecules.
    Type: Application
    Filed: October 7, 2015
    Publication date: April 7, 2016
    Inventors: Stuart Martin, Christopher M. Jewell, James I. Andorko, Elisabeth Lily Sooklal, Rebecca Whipple Bettes, Kristi Chakrabarti
  • Publication number: 20150374806
    Abstract: A method of inducing specific immune tolerance to myelin in an individual is provided. The method includes introducing directly into a lymph node of the individual an effective amount of a composition that contains a myelin antigen, a biodegradable material and at least one tolerogenic agent. The method is suitable for reducing the severity of symptoms of multiple sclerosis in individuals who suffer from primary-progressive multiple sclerosis (PPMS), and can halt or even reverse PPMS progression.
    Type: Application
    Filed: June 26, 2015
    Publication date: December 31, 2015
    Inventors: Christopher M. Jewell, James I. Andorko, Lisa H. Tostanoski